跳至主要内容
临床试验/NL-OMON45168
NL-OMON45168尚未招募不适用

Fluid phase biopsy (circulating tumour DNA and serum tumour markers) in patients with non-small cell lung cancer. - Fluid phase biopsy in NSCLC.

Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 1,190 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
1,190

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Inclusion criteria locally advanced stage disease (for both stage 1-2):
  • 1. 18 years of age, or above
  • 2. Histologically or cytologically confirmed diagnosis of NSCLC
  • 3. Stage II/III non-operable disease, without malignant pleural effusion
  • 4. Indication for concurrent chemoradiotherapy (NKI-AVL: 66Gy in 24 fractions with daily
  • low dose cisplatin 6mg/m2; University Hospital Leuven: 66Gy in 33 fractions with 3 weekly dose cisplatin 75mg/m2)
  • 5. Performance score: WHO 0-2 at study entry
  • 6. Signed written informed consent;Inclusion criteria advanced stage NSCLC
  • 1. 18 years of age, or above
  • 2. Histologically or cytologically confirmed diagnosis of NSCLC
  • 3. Advanced stage disease
  • 4. Indication for treatment
  • 5. Performance score: WHO 0-2 at study entry
  • 6. Signed written informed consent

排除标准

  • Unwillingness to participate in study

研究者

发起方
Antoni van Leeuwenhoek Ziekenhuis

相似试验

Fluid phase biopsy (circulating tumour DNA and serum... | 临床试验